CoChat

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy

Open access

Abstract

Ribozyme-directed cleavage of mutant mRNAs appears to be a potentially effective therapeutic measure for dominantly inherited diseases. We previously demonstrated that two ribozymes targeted to the P23H mutation in rhodopsin slow photoreceptor degeneration in transgenic rats for up to 3 months of age when injected before significant degeneration at postnatal day (P) 15. We now have explored whether ribozyme rescue persists at older ages, and whether ribozymes are effective when injected later in the degeneration after significant photoreceptor cell loss. Recombinant adeno-associated virus (rAAV) vectors incorporating a proximal bovine rod opsin promoter were used to transfer either hairpin or hammerhead ribozyme genes to photoreceptors. For the study of long-term survival, rAAV was administered by subretinal injection at P15, and the rats were allowed to live up to 8 months of age. For the study of late-stage gene transfer, rAAV was administered at P30 or P45, when 40–45% of the photoreceptors already had degenerated. Eyes were examined functionally by the electroretinogram and structurally by morphometric analysis. When injected at P15, expression of either ribozyme markedly slowed the rate of photoreceptor degeneration for at least 8 months and resulted in significantly greater electroretinogram amplitudes at least up to P180. When injected at P30 or P45, virtually the same number of photoreceptors survived at P130 as when injected at P15. Ribozyme rescue appears to be a potentially effective, long-term therapy for autosomal dominant retinal degeneration and is highly effective even when the gene transfer is done after significant photoreceptor cell loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.210319397

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 10

  1. E L Berson Invest Ophthalmol Visual Sci 34, 1659–1676 (1993).
  2. M B Gorin, J C S Breitner, P T V M De Jong, G S Hageman, C C W Klaver, M H Kuehn, J M Seddon Mol Vis 5, 29 (1999).
  3. D J Zack, M Dean, R S Molday, J Nathans, T M Redmond, E M Stone, A Swaroop, D Valle, B H Weber Mol Vis 5, 30 (1999).
  4. M Akimoto, S Miyatake, J Kogishi, M Hangai, K Okazaki, J C Takahashi, M Saiki, M Iwaki, Y Honda Invest Ophthalmol Visual Sci 40, 273–279 (1999).
  5. J J Rossi Ciba Found Symp 209, 195–204 (1997).
  6. P A Pavco, K S Bouhana, A M Gallegos, A Agrawal, K S Blanchard, S L Grimm, K L Jensen, L E Andrews, F E Wincott, P A Pitot, et al. Clin Cancer Res 6, 2094–2103 (2000).
  7. K A Drenser, A M Timmers, W W Hauswirth, A S Lewin Invest Ophthalmol Visual Sci 39, 681–689 (1998).
  8. K Unoki, M M LaVail Invest Ophthalmol Visual Sci 35, 907–915 (1994).
  9. J J Michon, Z L Li, N Shioura, R J Anderson, M O M Tso Invest Ophthalmol Visual Sci 32, 280–284 (1991).
  10. J Bennett, D Duan, J F Engelhardt, A M Maguire Invest Ophthalmol Visual Sci 38, 2857–2863 (1997).

Cited by

See all 203

Metadata

Authors
LaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A., Flannery, J. G., Lewin, A. S., & Hauswirth, W. W.
Affiliations
University of California, San Francisco (US)
Venue
Proceedings of the National Academy of Sciences
Published
2000-09-26
Volume
97
Issue
21
Pages
11488-11493
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2077508733
Cited by
203
References
38
Citations by year
2025: 2 · 2024: 3 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 5 · 2015: 8 · 2014: 9 · 2013: 6 · 2012: 12
FWCI
5.31
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • March of Dimes Foundation
  • Foundation Fighting Blindness
  • Research to Prevent Blindness (EY02162)
  • Macula Vision Research Foundation
  • National Institutes of Health (EY01919, EY02162)
  • National Eye Institute (EY-06842, EY02162, P30EY002162, EY-01919, R01EY011596, R01EY001919, P30EY008571, F32EY006842, R01EY011123, R01EY006842, T32EY007132)
  • National Institute of Neurological Disorders and Stroke (P01NS036302)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
retinitis pigmentosa, photoreceptor degeneration, adeno-associated virus vectors, hairpin ribozyme, hammerhead ribozyme, transgenic rats, electroretinogram, long-term survival
MeSH terms
Animals, Cell Survival, Photoreceptor Cells, Retinal Diseases, Genetic Therapy, RNA, Catalytic, Animals, Genetically Modified, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.